Pipeline breakthroughs & novel mechanisms

Anti-amyloid therapies (lecanemab, donanemab) expanding globally; Auvelity FDA-approved for agitation. Novel mechanisms: gene therapy, TREM2, tau-focused, copper-based drug, rapamycin analog. Major discovery: 'karyoptosis'—novel cell death mechanism (p38 MAP kinase/LaminB1) in Alzheimer's and FTD. Arc protein as Trojan horse for Tau spread. PWAS identifies peripheral immune proteins as targets. Astrocytic calcium signaling as early driver of default mode network dysfunction. Resilient brains show lower inflammation in immature neurons. Setback: semaglutide Phase 3 failed. $3M gift to USC targets APOE4-driven neuroinflammation. rTMS confirmed effective. 'Exercise Snacking' proposed. Prodrug strategy using hydrogen peroxide shows cognitive improvement. Tanycytes identified as CSF-to-blood bridge for Tau clearance. Zunveyl real-world data shows improvements. Genentech/Roche Brainshuttle open-label extension shows long-term safety. New: Roche AAIC data on trontinemab long-term safety and biomarker results; PrevenTRON Phase III design; NLRP3 inhibition as neuroimmune target. Also: autonomous robot delivering cognitive stimulation therapy at home shows feasibility for scalable low-burden intervention. KCL-286 (retinoic acid receptor-beta agonist) shows early promise in mouse model targeting DNA repair and neuroinflammation; Phase I safe in humans. Lilly to present donanemab long-term extension data at AAIC 2027, adding to durability evidence. New: ATP platform adaptive trial using dual-protein biomarker screening (pTau217 + NfL) for asymptomatic individuals, with tau vaccine arm—accelerates drug development. New: Neurogenesis resilience—keeping newborn neurons alive may protect cognition even with Alzheimer's pathology; postmortem and animal evidence shifts focus from amyloid to neurogenesis as therapeutic target. Annovis Bio fully enrolled Phase 3 buntanetap trial (850 patients, pTau217-confirmed early AD); dual symptomatic/disease-modifying design; data expected 2027-2028. Call-to-action to include atypical AD variants in trials—systematic exclusion leaves younger, non-amnestic patients without evidence-based treatments; concrete design strategies proposed. New: Non-drug treatment targeting cerebral blood flow shows 78% improvement rate in Alzheimer's, with persistent benefit after stopping—single trial, needs replication. New: AAIC 2026 preview interview with David Wolk highlights tau ASO trial (CELIA) and anti-amyloid therapy data. New: Lancet review on clinical trial inclusivity highlights gaps in representing older, comorbid populations—critical for translating trial results to real-world dementia care. New: Elixiron Immunotherapeutics reports positive Phase 2 interim data for enrupatinib (CSF-1R inhibitor) targeting neuroinflammation—clean safety, TSPO-PET target engagement, early cognitive signal (8-point MMSE gain in one responder); placebo-controlled study planned. New: UCSF launches combination therapy trial targeting both amyloid and tau, using blood tests for asymptomatic enrollment—parallels cancer treatment paradigm. Major breakthrough: Denali Therapeutics receives FDA approval for AVLAYAH, a transferrin receptor-based platform enabling BBB crossing for biologics—10-30x brain exposure for antibodies, 1000x for oligonucleotides. This unlocks Alzheimer's antibody and oligonucleotide delivery, fundamentally changing the drug development landscape. New: Trontinemab Phase 3 trial now recruiting 800 participants at 150 sites, placebo-controlled, brain shuttle technology—next step after AAIC 2027 long-term safety data. New: KCL-286 (retinoic acid receptor-beta agonist) shows early promise in mouse model targeting DNA repair and neuroinflammation; Phase I safe in humans. New: Phone-based cognitive rehab matches clinic outcomes for dementia, offering scalable low-barrier intervention for underserved areas. New: Non-drug 'physical therapy for the brain' shows real-world MCI improvement. New: Pepinemab (Vaccinex) advances to Phase 2b targeting astrocytes and neuroinflammation, with zero ARIA safety profile and independent biomarker validation—alternative to amyloid-focused therapies. New: FDA approved at-home starting dose for Leqembi—practical step reducing clinic burden. New: THN391 Phase 1 trial targeting early Alzheimer's with small vessel disease—basic safety/pharmacokinetics, no efficacy data yet. New: 40 Hz GENUS light/sound therapy 2-year pilot shows pTau217 drops in some patients, with sex/disease-onset differences—adds to non-invasive therapy evidence. New: Preliminary study shows medical cannabis eases agitation in advanced dementia (90% improvement), but needs replication; caution against self-administration. New: Anti-PD-L1 immune therapy Phase I positive—targets immune aging, reduces neuronal damage biomarkers; novel mechanism beyond amyloid. New: Phase II LiBBY trial on cannabis-based treatment for agitation in advanced dementia shows promising signal—presented at AAIC 2026, addresses top caregiver concern. New: Roche AAIC 2026 update on trontinemab: 92% amyloid clearance at 28 weeks with brain shuttle; PrevenTRON Phase III using pTau217 for asymptomatic enrollment; obicetrapib p-tau217 reduction in APOE4 carriers. New: Alzheimer's Tau Platform (ATP) master protocol details: dual biomarker screening (pTau217 + NfL), tau vaccine arm, adaptive design. New: Phenserine completed Phase 1 trials—modest pipeline progress.